Atria Investments Inc Makes New Investment in ICU Medical, Inc. (NASDAQ:ICUI)

Atria Investments Inc purchased a new stake in ICU Medical, Inc. (NASDAQ:ICUI) during the third quarter, HoldingsChannel.com reports. The firm purchased 1,251 shares of the medical instruments supplier’s stock, valued at approximately $228,000.

A number of other large investors also recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in ICU Medical by 0.5% in the first quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock valued at $263,226,000 after purchasing an additional 11,991 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of ICU Medical by 21.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 311,542 shares of the medical instruments supplier’s stock valued at $36,996,000 after acquiring an additional 55,588 shares during the period. Silvercrest Asset Management Group LLC boosted its stake in ICU Medical by 109.4% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock worth $29,882,000 after acquiring an additional 145,485 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in ICU Medical by 11.5% during the second quarter. Bank of New York Mellon Corp now owns 216,509 shares of the medical instruments supplier’s stock valued at $25,710,000 after purchasing an additional 22,310 shares during the period. Finally, Federated Hermes Inc. grew its holdings in ICU Medical by 9.3% during the second quarter. Federated Hermes Inc. now owns 215,808 shares of the medical instruments supplier’s stock valued at $25,627,000 after purchasing an additional 18,301 shares during the period. Institutional investors and hedge funds own 96.10% of the company’s stock.

Insider Buying and Selling at ICU Medical

In other news, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the sale, the vice president now directly owns 13,107 shares in the company, valued at $2,139,324.54. This trade represents a 16.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $17,096,771.78. The trade was a 10.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,502 shares of company stock valued at $6,573,496 in the last 90 days. 6.70% of the stock is currently owned by company insiders.

ICU Medical Trading Down 0.2 %

ICUI opened at $168.46 on Friday. The stock has a market capitalization of $4.12 billion, a P/E ratio of -36.86 and a beta of 0.66. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a 12 month low of $83.26 and a 12 month high of $196.26. The firm’s fifty day simple moving average is $176.22 and its 200 day simple moving average is $145.40.

Wall Street Analyst Weigh In

ICUI has been the topic of a number of recent analyst reports. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday. Jefferies Financial Group started coverage on ICU Medical in a research note on Monday, October 14th. They set a “hold” rating and a $183.00 price objective on the stock. KeyCorp boosted their target price on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, November 13th. Raymond James raised their price target on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, ICU Medical currently has a consensus rating of “Moderate Buy” and an average target price of $173.00.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.